Back to News
May 15, 2026 12:01 PM

Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease.

• Revolution Medicines stock is taking a hit today. Why is RVMD stock falling?

In May, the Food and Drug Administration (FDA) approved the company's expanded access program for its experimental pancreatic cancer drug, daraxonrasib. 

In April, Revolution Medicines shared positive topline results from its Phase 3 RASolute 302 trial of daraxonrasib for metastatic pancreatic cancer.

In the RASolute 302 trial, daraxonrasib showed statistically significant improvements in progression-free survival and overall survival, both critical endpoints for cancer therapies.

Daraxonrasib demonstrated a median overall survival of 13.2 months compared to 6.7 months for standard chemotherapy.